Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

January 31, 2018

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraordinary general meeting, whereby the company will receive approximately SEK 88 million before transaction costs.


The issue proceeds will primarily be invested in the development of new drug candidates, based on Xspray Pharma’s HyNap-platform. The share issue will be fully subscribed in accordance with separate agreements with the selected investors. Shareholders representing approximately 67.2 percent of Xspray Pharma’s shares have undertaken to vote in favor of the share issue at an extraordinary general meeting.

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. The company’s shares are admitted to trading on Nasdaq First North.

Vinge’s team consists of Dain Hård Nevonen, Sabina Börjesson, Nils Fredrik Dehlin and Ramin Baradaran.

Related

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025

Vinge has advised Eleda in connection with its acquisition of Rail Solutions Scandinavia AB, Gridtec AB, Quantity Surveying Konsult Stockholm AB, Voene AB, Vägservice centralen i Norden AB and Frästech AB.

Vinge has advised the leading infrastructure group Eleda in connection with its parallel acquisitions of Rail Solutions Scandinavia (railway maintenance), Gridtec (engineering consultancy in electric power), Quantity Surveying Konsult Stockholm (cost control and project management), Voene (traffic safety), Vägservice centralen i Norden and Frästech (road and bridge maintenance). The acquired businesses had a strong profitability with a combined turnover of approximately 200 MSEK in 2024.
June 04, 2025